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Abstract: Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carci-
noma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can
be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and
especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.1−3 Data on retreat-
ment of DAA failure patients using first-generation DAAs are limited.4−7 Recently, a second-generation
protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was
approved for retreatment after DAA failure.8 However, this and other second-generation regimens are not
available in many resource-limited countries or are not reimbursed by regular insurance, and recommen-
dations regarding the selection of retreatment regimens using first-generation DAAs are very important.
This study aimed to analyze patients who were re-treated with first-generation DAAs after failure of a
DAA combination therapy.
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INTRODUCTION 139 
Hepatitis C virus (HCV) infection is causing chronic liver disease, cirrhosis and 140 
hepatocellular carcinoma (HCC). By combining direct acting antivirals (DAAs), high 141 
sustained virologic response rates (SVR) can be achieved. RASs are commonly 142 
observed after DAA failure and especially NS5A RASs may impact retreatment 143 
options.1-3 Data on retreatment of DAA failure patients using first generation DAAs 144 
are limited.4-7 Recently, a second generation protease- and NS5A-inhibitor plus 145 
sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir, VOX/VEL/SOF) was approved for 146 
retreatment after DAA failure.8 However, this and other second generation regimens 147 
are not available in many resource-limited countries or are not reimbursed by regular 148 
insurance and recommendations regarding the selection of retreatment regimens 149 
using first generation DAAs are very important. This study aimed to analyze patients 150 
who were retreated with first generation DAAs after failure to a DAA combination 151 
therapy.  152 
 153 
PATIENTS & METHODS 154 
Serum of patients with chronic hepatitis C was collected at different European study 155 
sites as part of a resistance database.2 We searched the database until October 1st, 156 
2017 for patients with a DAA failure.  157 
Data was collected retrospectively and recommendations for retreatment were given 158 
in line with the EASL/AASLD guidelines. However, individual retreatment strategies 159 
were at the treating physician’s discretion. A sustained virologic response was 160 
defined as negative HCV RNA 12 weeks after end of retreatment (SVR12). We 161 
applied a modified intention-to-treat (mITT) analysis including patients with 162 
completed retreatment and FU12. The study was conducted in accordance with the 163 
8 
Declaration of Helsinki and approved by the ethics committee of the University 164 
Hospital Frankfurt. 165 
HCV NS3, NS5A and NS5B PCR and sequencing analyses were conducted as 166 
described previously.2 167 
 168 
RESULTS 169 
We investigated a cohort 631 DAA failure patients and 47% (n=262/558) of eligible 170 
patients completed retreatment (Supp. Fig. 1).  171 
Overall 84% of NS5Ai/SOF failures infected with GT1 achieved SVR. The majority of 172 
patients received a regimen including a PI plus SOF (SMV/SOF±RBV, 173 
SMV/SOF+DCV/LDV, PrOD/SOF±RBV, GZR/EBR+SOF) and the SVR rate was 174 
91%. All patients without NS5A RASs achieved SVR, while the SVR rate was 90% in 175 
presence of RASs and Y93 RASs reduced SVR rates. A PI-based regimen without 176 
SOF (PrOD±RBV, GZR/EBR) was less effective (82% SVR) with slightly lower SVR 177 
rates in GT1a compared to 1b. For PI-based regimens in absence of RASs, the SVR 178 
rate was 93% and NS5A RASs reduced SVR rates. A repetition of NS5Ai/SOF 179 
without a PI was ineffective with 68% SVR. Here, in absence of RAS, the SVR rate 180 
reached 88% and was 50% only in presence of RAS (Fig. 1A-D). 181 
All GT3 DCV/SOF failures were retreated NS5Ai/SOF-based and 60% achieved 182 
SVR. The majority of patients harbored NS5A RASs (93%), and SVR rates were 183 
higher in absence of cirrhosis or absence of Y93H (Fig. 1E/F). We detected no 184 
statistically significant differences between SVR and failure patients concerning the 185 
presence of cirrhosis and other clinical parameters (Supp. Table 1). Data regarding 186 
treatment adherence, liver fibrosis and portal hypertension was not available as 187 
9 
patients with decompensated cirrhosis were not included and therapies were 188 
conducted at external centers. 189 
 190 
DISCUSSION 191 
The management of DAA failure patients remains a challenge. Our study comprises 192 
a very large European real-world DAA failure cohort and 85% achieved SVR upon 193 
retreatment with first generation DAAs.  194 
We demonstrated high SVR rates after NS5Ai/SOF failure in GT1, when SOF was 195 
reused in combination with a new DAA class (i.e. switch from a NS5Ai to a PI). 196 
However, SVR rates were slightly reduced in presence of high-level resistant Y93 197 
RASs. A retreatment based on the addition of a new DAA class without SOF as well 198 
as repetition of NS5Ai/SOF led to reduced SVR rates in presence of NS5A RASs and 199 
especially GT1a patients with high-level resistant Q30R responded poorly. These 200 
strategies may be considered in the absence of NS5A RASs only.6 201 
In DCV/SOF failures with GT3, the prevalence of NS5A RASs as well as cirrhosis 202 
was considerably higher compared to GT1. SVR rates to a NS5Ai/SOF repetition, 203 
were low especially in presence of cirrhosis or Y93H. Interestingly, in a recent study 204 
with inclusion of a PI (VOX/VEL/SOF) the majority of treatment failures had GT3.8 205 
Thus, retreatment of GT3 remains a challenge. 206 
Limitations of this study include the retrospective data analysis and small patient 207 
numbers in specific groups. Taken together, for GT1-infected patients including a 208 
new DAA class plus sofosbuvir is highly effective, whereas retreatment of GT3 is 209 
requiring multiple targeted regimens including a second generation PI. The results of 210 
this real-world study may be of importance for many areas of the world where second 211 
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FIGURE LEGENDS: 243 
 244 
Fig. 1: Retreatment in patients with NS5Ai/SOF failure. SVR rates according to 245 
(A) retreatment regimens (GT1); RASs in (B) patients who received a new DAA class 246 
plus SOF (GT1); (C) individuals who were retreated with new DAA class without SOF 247 
(GT1); (D) patients who received a repetition of NS5Ai/SOF (GT1); (E) retreatment 248 
regimens (GT3); RASs in (F) DCV/SOF failures (GT3).  249 
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Supporting Table 1. Characteristics of patients eligible for retreatment infected with HCV genotype 1 (n=251) and genotype 3 (n=63). 
 
































GT1, subtype 1a 7 (47) 2 (67)  9 (69) 36 (50) 7 (50) 69 (52) - - - 
GT1, subtype 1b 8 (53) 1 (33)  4 (31) 36 (50) 7 (50) 63 (47) - - - 
GT1, subtype other - - - - - 2 (1) - - - 
GT3, subtype 3a - - - - - - 8 (89) 6 (100) 40 (83) 
GT3, subtype 3b - - - - - - 1 (11) -  1 (2) 
GT3, subtype 3h - - - - - - - -  1 (2) 
GT3, subtype other - - - - - - - -   6 (13) 
Male gender 13 (87) 2 (67) 8 (62) 56 (78) 12 (86) 98 (73) 8 (89) 6 (100) 41 (85) 
          
Mean Age 53 (33-63) 58 (54-61) 54 (28-71) 59 (36-77) 57 (30-74) 57 (24-84) 51 (37-60) 54 (45-54) 50 (31-65) 


















Prior IFN-experience 9 (69) 
n=13* 














RBV included in 1
st




 DAA treatment n=15* n=3* n=11* n=63* n=13* n=107* n=9* n=6* n=40* 
8 weeks - - - 20 (32) 3 (23) 37 (35) - - - 
12 weeks 7 (47) 2 (67) 7 (64) 36 (57) 10 (77) 61 (57) 7 (78) 4 (67) 28 (70) 
24 weeks 8 (53) 1 (33)  3 (27)  7 (11) - 8 (7) 2 (22) 2 (33) 12 (30) 
Early discont. - - 1 (9) - -  1 (1) - - - 
          
Retreatment    
 
n.a. 
   
 
n.a. 
   
 
n.a. 
RBV included in Retreatment 13 (87) 1 (33) 38 (53) 9 (64) 5 (71) 5 (83) 
Duration Retreatment       
12 weeks 7 (47) 2 (67) 52 (72) 8 (57) 6 (67) 4 (67) 
24 weeks 8 (53) 1 (33) 19 (26) 5 (38) 3 (33) 2 (33)
+
 
Early discont. - - - 1 (5) - - 
 
Resistance after DAA failure 
Pts. with NS3 RASs
#


















Pts. with NS5A RASs
#












8 (89) 6 (100)  36 (82) 
n=44* 
Pts. with NS3any + NS5Aany 2 1 1 5 - 24 - - - 
NS3 Q80K 2 1 3 13 - 26 - - - 
NS3 R155K, A156any, D168any - - 2 1 - 6 - - - 
NS5B S282T - - - - - 2 - - 1 
DAA, direct acting antiviral; DCV, daclatasvir; FAIL, failure; IFN, interferon; LDV, ledipasvir; n.a., not applicable; NS3, nonstructural protein 3; NS5A, nonstructural protein 5A; SOF, sofosbuvir; 
pts., patients; RBV, ribavirin; Re-Tx, retreatment. *Number of patients with available data; 
#
Rate of pts. with RASs; 
+
One pt. received 36 weeks LDV/SOF; 
§
status of October 2017 (see methods). 

